Lead Product(s) : ABV-1701,Adipic Dihydrazide
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ABV-1701 is a hyaluronic acid derived hydrogel therapy which is currently being investigated for the treatment of retinal detachment and vitreous hemorrhage.
Product Name : Vitargus
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 04, 2023
Lead Product(s) : ABV-1701,Adipic Dihydrazide
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ABV-1701,Adipic Dihydrazide
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ABVC BioPharma Vitargus Phase II Study Received Ethical Approval at Sydney Eye Hospital in Australia
Details : ABV-1701 is a hyaluronic acid derived hydrogel therapy which is currently being investigated for the treatment of retinal detachment and vitreous hemorrhage.
Product Name : Vitargus
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 22, 2023
Lead Product(s) : ABV-1701,Adipic Dihydrazide
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ABV-1701,Adipic Dihydrazide
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Vitargus (hyaluronic acid-derived therapy) is a next-generation vitreous substitute that a First-In-Human clinical trial has demonstrated is a significant upgrade to current vitreous substitutes available to eye surgeons.
Product Name : Vitargus
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 17, 2022
Lead Product(s) : ABV-1701,Adipic Dihydrazide
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ABV-1701,Adipic Dihydrazide
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ABVC BioPharma Selects Additional Vitargus® Phase II Study Site
Details : Vitargus (Hyaluronic Acid Derived Therapy) is a next-generation vitreous substitute that a First-In-Human clinical trial has demonstrated is a significant upgrade to current vitreous substitutes available to eye surgeons.
Product Name : Vitargus
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 09, 2022
Lead Product(s) : ABV-1701,Adipic Dihydrazide
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ABV-1701,Adipic Dihydrazide
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ABVC BioPharma Provides Vitargus® Update
Details : Vitargus/ABV-1701 (hyaluronic acid derived therapy) is a next-generation vitreous substitute that a First-In-Human clinical trial has demonstrated is a significant upgrade to current vitreous substitutes available to eye surgeons.
Product Name : Vitargus
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 30, 2022
Lead Product(s) : ABV-1701,Adipic Dihydrazide
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ABV-1701,Adipic Dihydrazide
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ABVC BioPharma Announces Vitargus® Phase II Study Plan Approved by HREC in Australia
Details : ABV-1701 is an injectable, in-situ-forming hydrogel, composed of oxidized hyaluronic acid (oxi-HA) and adipic acid dihydrazide (ADH) and is used for the treatment of uncomplicated retinal detachment.
Product Name : Vitargus
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 10, 2022
Lead Product(s) : ABV-1701,Adipic Dihydrazide
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable